Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYMPHONY: Macitentan in PAH
NCT01841762Phase 3Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Apr 2013
- Primary completion
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of macitentan in pulmonary arterial hypertension (PAH), sponsored by Actelion Pharmaceuticals Ltd. Primary endpoints: Development and Refinement of the Patient-reported Outcome Measure of Symptoms and Their Impact in PAH (the PAH-SYMPACT) at 16 weeks, Validation of the PAH-SYMPACT, With Reliability Assessed Via Test-retest Reliability at 1 week and 1 more. Started Apr 2013; status: completed.
02
Drugs
macitentan
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT01841762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01841762.